Emerging roles of deubiquitinating enzymes in human cancer

Acta Pharmacologica Sinica

Volumn 28, Issue 9, 2007, Pages 1325-1330

  Yang, Jin Ming ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Deubiquitinating enzymes; Ubiquitin

Indexed keywords

BAP1 ENZYME; BORTEZOMIB; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CYLD ENZYME; CYSTEINE PROTEINASE; DEUBIQUITINATING ENZYME; DUB 2 ENZYME; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTERASE; GENE PRODUCT; HUMORF8 ENZYME; PROTEASOME; PROTEIN MDM2; PROTEIN P53; PROTEIN PGP9.5; TUMOR MARKER; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; UBP 43 ENZYME; UNCLASSIFIED DRUG; USP11 ENZYME; USP28 ENZYME; USP2A ENZYME; USP7 ENZYME;

BIOGENESIS; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER PAIN; CANCER RESEARCH; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; COLORECTAL CANCER; COVALENT BOND; DNA DAMAGE; DNA REPAIR; ENZYME INACTIVATION; ENZYME MECHANISM; GENE FUNCTION; HUMAN; NERVE CELL DIFFERENTIATION; ONCOGENE; PANCREAS CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STRESS; THYROID CARCINOMA; TUMOR SUPPRESSOR GENE; UBIQUITINATION; VIRUS INFECTION;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; UBIQUITIN THIOLESTERASE; UBIQUITINATION;

EID: 34548434688     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00687.x     Document Type: Review

References (53)

1. Peters JM, Harris JR, Finley D. Ubiquitin and the biology of the cell. New York and London : Plenum, 1998.
2. Wilkinson KD. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997 11 : 1245 56.
3. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000 11 : 141 8.
4. Chain DG, Casadio A, Schacher S, Hegde AN, Valbrun M, Yamamoto N, et al. Mechanisms for generating the autonomous cAMP-dependent protein kinase required for long-term facilitation in Aplysia. Neuron 1999 22 : 147 56.
5. Verma R, Aravind L, Oania R, McDonald WH, Yates JR III., Koonin EV, et al. Role of Rpn11 metalloprotease in deubiqui-tination and degradation by the 26S proteasome. Science 2002 298 : 611 5.
6. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 2002 419 : 403 7.
7. Hanna J, Hathaway NA, Tone Y, Crosas B, Elsasser S, Kirkpatrick DS, et al. Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell 2006 127 : 99 111.
8. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002 111 : 209 18.
9. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989 246 : 670 3.
10. Dhillon AP, Rode J, Dhillon DP, Moss E, Thompson RJ, Spiro SG, et al. Neural markers in carcinoma of the lung. Br J Cancer 1985 51 : 645 52.
11. Rode J, Dhillon AP, Doran JF, Jackson P, Thompson RJ. PGP 9.5, a new marker for human neuroendocrine tumours. Histopathology 1985 9 : 147 58.
12. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999 155 : 711 5.
13. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000 6 : 4764 7.
14. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002 8 : 192 5.
15. Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, et al. Expression of protein gene product 9.5 (PGP9. 5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 2004 127 : 292 8.
16. Al-Katib AM, Mohammad RM, Maki A, Smith MR. Induced expression of a ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia. Cell Growth Differ 1995 6 : 211 7.
17. Mohammad RM, Maki A, Pettit GR, Al-Katib AM. Bryostatin 1 induces ubiquitin COOH-terminal hydrolase in acute lympho-blastic leukemia cells. Enzyme Protein 1996 49 : 262 72.
18. Caballero OL, Resto V, Patturajan M, Meerzaman D, Guo MZ, Engles J, et al. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene 2002 21 : 3003 10.
19. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000 183 : 10 17.
20. Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000 6 : 4073 81.
21. Yao J, Eu KW, Seow-Choen F, Cheah PY. Down-regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer 2000 89 : 213 6.
22. Hirano K, Minamoto T. Altered expression of p53 and p27 proteins, alone or combined, as a predictor of metastatic potential in early invasive carcinoma of colon and rectum - a comparative clinicopathologic and molecular analysis. Cancer Detect Prev 2000 24 : 343 55.
23. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracel-lular proteolysis in lymphoma cells. Nat Cell Biol 2001 3 : 283 8.
24. Rolen U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, et al. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog 2006 45 : 260 9.
25. Ciechanover A, DiGiuseppe JA, Bercovich B, Orian A, Richter JD, Schwartz AL, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 1991 88 : 139 43.
26. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996 56 : 2649 54.
27. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res 2003 5 : 8 15.
28. Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol 2003 13 : 29 40.
29. Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003 13 : 15 28.
30. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002 416 : 648 53.
31. Cummins JM, Vogelstein B. HAUSP is required for p53 destabilization. Cell Cycle 2004 3 : 689 92.
32. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004 13 : 879 86.
33. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004 5 : 253 61.
34. Schoenfeld AR, Apgar S, Dolios G, Wang R, Aaronson SA. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol 2004 24 : 7444 55.
35. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006 126 : 529 42.
36. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998 16 : 1097 112.
37. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003 424 : 797 801.
38. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003 424 : 793 6.
39. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003 424 : 801 5.
40. Liu LQ, Ilaria R Jr., Kingsley PD, Iwama A, van Etten RA, Palis J, et al. A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 1999 19 : 3029 38.
41. Migone TS, Humbert M, Rascle A, Sanden D, D'Andrea A, Johnston JA. The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal. Blood 2001 98 : 1935 41.
42. Janssen JW, Schleithoff L, Bartram CR, Schulz AS. An onco-genic fusion product of the phosphatidylinositol 3-kinase p85beta subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 1998 16 : 1767 72.
43. Geddy PM, Gray S, Reid WA. Mast cell density and PGP 9.5-immunostained nerves in angioleiomyoma: their relationship to painful symptoms. Histopathology 1993 22 : 387 90.
44. Zhang HW, Iida Y, Andoh T, Nojima H, Murata J, Saiki I, et al. Mechanical hypersensitivity and alterations in cutaneous nerve fibers in a mouse model of skin cancer pain. J Pharmacol Sci 2003 167 70.
45. Sasaki H, Yukiue H, Moriyama S, Kobayashi Y, Nakashima Y, Kaji M, et al. Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn J Clin Oncol 2001 31 : 532 5.
46. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 2001 61 : 7908 12.
47. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004 303 : 844 8.
48. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002 628 34.
49. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 2003 29 (Suppl 1 41 8.
50. Richardson P. Clinical update: proteasome inhibitors in hemato-logic malignancies. Cancer Treat Rev 2003 29 (Suppl 1 33 9.
51. Orlowski RZ, Dees EC. The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 2003 5 : 1 7.
52. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 2003 41 (Suppl 1 S89 96.
53. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003 10 : 837 46.